Daniel Loeb’s Wall St Hedge Fund Third Point Raises Bets On Corporate Credit Crunch

An “obsession” around balance sheet strength and debt is creating a new wave of investment bets for the influential Wall Street hedge fund run by Daniel Loeb.
Surging interest rates have delivered new investment opportunities for Wall Street hedge fund Third Point. Picture: Getty Images/AFP

Eric Johnston

Daniel Loeb’s Wall St Hedge Fund Third Point Raises Bets On Corporate Credit Crunch

November 15, 2023
An “obsession” around balance sheet strength and debt is creating a new wave of investment bets for the influential Wall Street hedge fund run by Daniel Loeb.
Read Transcript

An “obsession” around balance sheet strength and debt is creating a new wave of investment bets for the influential Wall Street hedge fund run by Daniel Loeb.

This could extend to his $US11bn ($17bn) Third Point fund putting more pressure on companies to force through asset sales.

The comments by Loeb in his latest quarterly update to investors, comes as the hedge fund boss is scheduled to headline the Sohn Hearts & Minds investment conference in Sydney on Friday. All the proceeds of the conference go to medical research.

With real interest rates firmly in positive territory and now sitting at the highest level since the global financial crisis, Loeb’s Third Point fund has narrowed in on how companies are refinancing debt. Indeed, some may even struggle as borrowing costs soar.

Daniel Loeb of Third Point says the way companies are dealing with the high cost of debt is delivering new opportunities. Picture: Bloomberg

“It is hard to overstate the market’s current obsession with balance sheet strength,” Loeb tells investors.

“This is a growing area of focus for the investment team, as major systematic moves generally create great idiosyncratic opportunities that can only be uncovered through old-fashioned fundamental research”.

Investment returns will be found by distinguishing the companies that have “real leverage problems versus perceived leverage problems,” he said.

This involves narrowing in on asset sale opportunities, capital structures, and cash flow statements, Loeb says.

In recent years, Loeb has made high profile pushes agitating for changes at a string of companies including Disney, Nestle and Shell.

Loeb launched Third Point in 1996 and the fund had some of its best returns after betting on troubled Greek bonds during the Euro crisis of early last decade.

Third Point has seen a rare stumble this year after missing much of the initial boom in AI-backed tech stocks.

Loeb’s flagship offshore fund returned minus 3.9 per cent in the calendar year to date. This compares to the MSCI World Index of 11.6 per cent and the S&P 500’s total return of 11.6 per cent.

Third Point has delivered average annualised returns of 12.7 per cent after fees since inception, compared to 7.1 per cent for the MSCI World Index.

Returns were minus 0.9 per cent for the September quarter, with gains in Third Point’s long exposure fund offsetting losses in the hedge fund bets.

The top stocks were UBS, Vistra Corp Shell and Danaher Corp. This was offset be exposure to Pacific Gas & Electric Co, tech major Microsoft Corp, Hertz and Luxury brands business LVMH.

With bond market sell-off in recent months driving wild swings in stocks, Loeb believes the market reaction to macro developments was still “rational”.

This resulted in the continued underperformance of unprofitable growth stocks, highly-levered companies, and bonds proxies like utilities, real estate and consumer staples.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

An “obsession” around balance sheet strength and debt is creating a new wave of investment bets for the influential Wall Street hedge fund run by Daniel Loeb.

This could extend to his $US11bn ($17bn) Third Point fund putting more pressure on companies to force through asset sales.

The comments by Loeb in his latest quarterly update to investors, comes as the hedge fund boss is scheduled to headline the Sohn Hearts & Minds investment conference in Sydney on Friday. All the proceeds of the conference go to medical research.

With real interest rates firmly in positive territory and now sitting at the highest level since the global financial crisis, Loeb’s Third Point fund has narrowed in on how companies are refinancing debt. Indeed, some may even struggle as borrowing costs soar.

Daniel Loeb of Third Point says the way companies are dealing with the high cost of debt is delivering new opportunities. Picture: Bloomberg

“It is hard to overstate the market’s current obsession with balance sheet strength,” Loeb tells investors.

“This is a growing area of focus for the investment team, as major systematic moves generally create great idiosyncratic opportunities that can only be uncovered through old-fashioned fundamental research”.

Investment returns will be found by distinguishing the companies that have “real leverage problems versus perceived leverage problems,” he said.

This involves narrowing in on asset sale opportunities, capital structures, and cash flow statements, Loeb says.

In recent years, Loeb has made high profile pushes agitating for changes at a string of companies including Disney, Nestle and Shell.

Loeb launched Third Point in 1996 and the fund had some of its best returns after betting on troubled Greek bonds during the Euro crisis of early last decade.

Third Point has seen a rare stumble this year after missing much of the initial boom in AI-backed tech stocks.

Loeb’s flagship offshore fund returned minus 3.9 per cent in the calendar year to date. This compares to the MSCI World Index of 11.6 per cent and the S&P 500’s total return of 11.6 per cent.

Third Point has delivered average annualised returns of 12.7 per cent after fees since inception, compared to 7.1 per cent for the MSCI World Index.

Returns were minus 0.9 per cent for the September quarter, with gains in Third Point’s long exposure fund offsetting losses in the hedge fund bets.

The top stocks were UBS, Vistra Corp Shell and Danaher Corp. This was offset be exposure to Pacific Gas & Electric Co, tech major Microsoft Corp, Hertz and Luxury brands business LVMH.

With bond market sell-off in recent months driving wild swings in stocks, Loeb believes the market reaction to macro developments was still “rational”.

This resulted in the continued underperformance of unprofitable growth stocks, highly-levered companies, and bonds proxies like utilities, real estate and consumer staples.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 15, 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
January 18, 2023

Claremont Global: Investment Case for Nike

Equity Mates are joined by Head of Claremont Global Bob Desmond to discuss his 2022 conference pick, Nike. In the episode Bob unpacks the key metrics, the bull case and the bear case for Nike.

Read More
January 5, 2023

Why Transurban will always be one step ahead of inflation

Loathed by motorists, but loved by investors. Transurban came under focus when Catherine Allfrey nominated the roads operator as her top pick at the recent Sohn Hearts & Minds Conference.

Read More
November 18, 2022

Behind the mega-themes shaping top stockpickers

These are the mega-themes the smartest minds in the market are now firmly getting behind which they believe can help them deliver outsized profits.

Read More
November 18, 2022

Don’t rush to invest yet, fund manager tells Sohn event

Fund manager turned anti-corruption campaigner Bill Browder is advising investors to hang on to their cash until central banks stop raising interest rates and the cost of living starts to come down.

Read More
November 18, 2022

Fund managers go global for top Sohn conference stock picks over Aussie companies

SH&M had before Friday’s event made more than $40m in collective donations to medical research.

Read More
November 18, 2022

Fundies and billionaires party in Hobart

Two hundred of Australia’s best and brightest money managers, bankers and entrepreneurs toasted the seventh Sohn Hearts and Minds conference at David Walsh’s MONA.

Read More
November 18, 2022

Hearts racing: Rich listers rendezvous for speed-dating style stock picking

A room filled with 700 of the country’s financial luminaries and billionaires is a difficult place to pitch an investment idea but it’s a great place to raise money for charity.

Read More
November 18, 2022

How MONA’s David Walsh shocked our top stock pickers

Professional gambler and arts impresario David Walsh had a brutal message for successful top money managers – you may just be lucky.

Read More
November 18, 2022

Why Sohn’s top stock pickers want investors to play it safe

Top global money managers are telling investors to steer clear of companies that don’t make money and invest instead in unloved but profitable businesses.

Read More
November 17, 2022

Five years on, what are the best Sohn stock picks to date?

Some of the top fund managers in the country will on Friday pitch their best investment ideas to the Sohn Hearts & Minds conference.

Read More
November 17, 2022

Low debt counts for everything, says Perpetual’s Aboud

Perpetual’s top stock picker Anthony Aboud makes his money running against the crowd and this is why property trusts like Charter Hall are sitting right the top his list right now.

Read More
November 17, 2022

Perpetual’s Aboud says bet on balance sheets in turbulent markets

Perpetual’s Anthony Aboud says companies with strong balance sheets will finally be rewarded for their discipline in a time of global market upheaval.

Read More
November 16, 2022

How Gerry Cardinale of RedBird Capital tries to double his money investing in sport

The owner of AC Milan and a host of other soccer, cricket, baseball and ice hockey assets is trying to double his money in the ‘resilient’ asset class.

Read More
November 14, 2022

Think outside the box for green investment opportunities

James Miller, Portfolio Manager at Firetrail Investments, believes investors need to stop seeing the global decarbonisation push as a risk – and start seeing it as an opportunity.

Read More
November 14, 2022

Tim Carleton is backing the Aussie dream all the way

Carleton’s conviction will be on full display on Friday when he makes his third appearance at the Sohn Hearts & Minds Conference, where stock-pickers share their best ideas in the name of medical research.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.